1887

Abstract

Respiratory syncytial virus (RSV) is the most common cause of respiratory infection in infants and the elderly, and no vaccine against this virus has yet been licensed. Here, we report a recombinant PR8 influenza virus with the RSV fusion (F) protein epitopes of the subgroup A gene inserted into the influenza virus non-structural (NS) gene (rFlu/RSV/F) that was generated as an RSV vaccine candidate. The rescued viruses were assessed by microscopy and Western blotting. The proper expression of NS1, the NS gene product, and the nuclear export protein (NEP) of rFlu/RSV/F was also investigated using an immunofluorescent assay. The rescued virus replicated well in the MDCK kidney cell line, A549 lung adenocarcinoma cell line and CNE-2Z nasopharyngeal carcinoma cell line. BALB/c mice immunized intranasally with rFlu/RSV/F had specific haemagglutination inhibition antibody responses against the PR8 influenza virus and RSV neutralization test proteins. Furthermore, intranasal immunization with rFlu/RSV/F elicited T helper type 1-dominant cytokine profiles against the RSV strain A2 virus. Taken together, our findings suggested that rFlu/RSV/F was immunogenic and warrants further development as a promising candidate vaccine.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.064105-0
2014-09-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/9/1886.html?itemId=/content/journal/jgv/10.1099/vir.0.064105-0&mimeType=html&fmt=ahah

References

  1. Chen Z., Wang W., Zhou H., Suguitan A. L. Jr, Shambaugh C., Kim L., Zhao J., Kemble G., Jin H.. ( 2010;). Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. . J Virol 84:, 44–51. [CrossRef][PubMed]
    [Google Scholar]
  2. Collins P. L., Melero J. A.. ( 2011;). Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. . Virus Res 162:, 80–99. [CrossRef][PubMed]
    [Google Scholar]
  3. De Baets S., Schepens B., Sedeyn K., Schotsaert M., Roose K., Bogaert P., Fiers W., Saelens X.. ( 2013;). Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85–93 CTL epitope reduces RSV replication in mice. . J Virol 87:, 3314–3323. [CrossRef][PubMed]
    [Google Scholar]
  4. de Goede A. L., Boers P. H., Dekker L. J., Osterhaus A. D., Gruters R. A., Rimmelzwaan G. F.. ( 2009;). Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. . Vaccine 27:, 5735–5739. [CrossRef][PubMed]
    [Google Scholar]
  5. Fuller H., Del Mar C.. ( 2006;). Immunoglobulin treatment for respiratory syncytial virus infection. . Cochrane Database Syst Rev (4), CD004883.[PubMed]
    [Google Scholar]
  6. Fuller H. L., Del Mar C. B.. ( 2010;). WITHDRAWN: immunoglobulin treatment for respiratory syncytial virus infection. . Cochrane Database Syst Rev (9), CD004883.[PubMed]
    [Google Scholar]
  7. He Q., Martinez-Sobrido L., Eko F. O., Palese P., Garcia-Sastre A., Lyn D., Okenu D., Bandea C., Ananaba G. A.. & other authors ( 2007;). Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. . Immunology 122:, 28–37. [CrossRef][PubMed]
    [Google Scholar]
  8. Hoffmann E., Stech J., Guan Y., Webster R. G., Perez D. R.. ( 2001;). Universal primer set for the full-length amplification of all influenza A viruses. . Arch Virol 146:, 2275–2289. [CrossRef][PubMed]
    [Google Scholar]
  9. Horimoto T., Iwatsuki-Horimoto K., Hatta M., Kawaoka Y.. ( 2004;). Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components. . Microbes Infect 6:, 579–583. [CrossRef][PubMed]
    [Google Scholar]
  10. Jones B. G., Sealy R. E., Rudraraju R., Traina-Dorge V. L., Finneyfrock B., Cook A., Takimoto T., Portner A., Hurwitz J. L.. ( 2012;). Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. . Vaccine 30:, 959–968. [CrossRef][PubMed]
    [Google Scholar]
  11. Kamphuis T., Meijerhof T., Stegmann T., Lederhofer J., Wilschut J., de Haan A.. ( 2012;). Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. . PLoS ONE 7:, e36812. [CrossRef][PubMed]
    [Google Scholar]
  12. Kittel C., Sereinig S., Ferko B., Stasakova J., Romanova J., Wolkerstorfer A., Katinger H., Egorov A.. ( 2004;). Rescue of influenza virus expressing GFP from the NS1 reading frame. . Virology 324:, 67–73. [CrossRef][PubMed]
    [Google Scholar]
  13. Kittel C., Ferko B., Kurz M., Voglauer R., Sereinig S., Romanova J., Stiegler G., Katinger H., Egorov A.. ( 2005;). Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. . J Virol 79:, 10672–10677. [CrossRef][PubMed]
    [Google Scholar]
  14. Li Z. N., Mueller S. N., Ye L., Bu Z., Yang C., Ahmed R., Steinhauer D. A.. ( 2005;). Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity. . J Virol 79:, 10003–10012. [CrossRef][PubMed]
    [Google Scholar]
  15. Miyahira Y., García-Sastre A., Rodriguez D., Rodriguez J. R., Murata K., Tsuji M., Palese P., Esteban M., Zavala F., Nussenzweig R. S.. ( 1998;). Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. . Proc Natl Acad Sci U S A 95:, 3954–3959. [CrossRef][PubMed]
    [Google Scholar]
  16. Neumann G., Kawaoka Y.. ( 2001;). Reverse genetics of influenza virus. . Virology 287:, 243–250. [CrossRef][PubMed]
    [Google Scholar]
  17. Oshansky C. M., Zhang W., Moore E., Tripp R. A.. ( 2009;). The host response and molecular pathogenesis associated with respiratory syncytial virus infection. . Future Microbiol 4:, 279–297. [CrossRef][PubMed]
    [Google Scholar]
  18. Percy N., Barclay W. S., García-Sastre A., Palese P.. ( 1994;). Expression of a foreign protein by influenza A virus. . J Virol 68:, 4486–4492.[PubMed]
    [Google Scholar]
  19. Robinson K. A., Odelola O. A., Saldanha I. J., McKoy N. A.. ( 2012;). Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. . Cochrane Database Syst Rev 2:, CD007743.[PubMed]
    [Google Scholar]
  20. Sawada A., Komase K., Nakayama T.. ( 2011;). AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. . Vaccine 29:, 1481–1490. [CrossRef][PubMed]
    [Google Scholar]
  21. Schmidt M. R., McGinnes L. W., Kenward S. A., Willems K. N., Woodland R. T., Morrison T. G.. ( 2012;). Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. . J Virol 86:, 11654–11662. [CrossRef][PubMed]
    [Google Scholar]
  22. Sereinig S., Stukova M., Zabolotnyh N., Ferko B., Kittel C., Romanova J., Vinogradova T., Katinger H., Kiselev O., Egorov A.. ( 2006;). Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. . Clin Vaccine Immunol 13:, 898–904. [CrossRef][PubMed]
    [Google Scholar]
  23. Singh S. R., Dennis V. A., Carter C. L., Pillai S. R., Moore E. G.. ( 2007;). Respiratory syncytial virus recombinant F protein (residues 255–278) induces a helper T cell type 1 immune response in mice. . Viral Immunol 20:, 261–275. [CrossRef][PubMed]
    [Google Scholar]
  24. Strobel I., Krumbholz M., Menke A., Hoffmann E., Dunbar P. R., Bender A., Hobom G., Steinkasserer A., Schuler G., Grassmann R.. ( 2000;). Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. . Hum Gene Ther 11:, 2207–2218. [CrossRef][PubMed]
    [Google Scholar]
  25. Stukova M. A., Sereinig S., Zabolotnyh N. V., Ferko B., Kittel C., Romanova J., Vinogradova T. I., Katinger H., Kiselev O. I., Egorov A.. ( 2006;). Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. . Tuberculosis (Edinb) 86:, 236–246. [CrossRef][PubMed]
    [Google Scholar]
  26. Webster R. G., Kawaoka Y., Taylor J., Weinberg R., Paoletti E.. ( 1991;). Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. . Vaccine 9:, 303–308. [CrossRef][PubMed]
    [Google Scholar]
  27. Yang P., Duan Y., Wang C., Xing L., Gao X., Tang C., Luo D., Zhao Z., Jia W.. & other authors ( 2011;). Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. . Vaccine 29:, 698–705. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.064105-0
Loading
/content/journal/jgv/10.1099/vir.0.064105-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error